Lecanemab Autoinjector Injection, Solution
NDC Package 62856-220-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Lecanemab Autoinjector (lecanemab-irmb) injection is lEQEMBI is indicated for the treatment of Alzheimer’s disease. This formulation utilizes a injection, solution delivery system. Marketed by Eisai Inc., this product is identified by NDC 62856-220 and is authorized under FDA application BLA761375.

Identification & Billing

NDC Package Code
62856-220-01
Package Description
1 SYRINGE, PLASTIC in 1 CARTON / 1.8 mL in 1 SYRINGE, PLASTIC (62856-220-10)
Product Code
62856-220
11-Digit Billing Format
62856022001
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.

Clinical Specifications

Proprietary Name
Lecanemab Autoinjector
Non-Proprietary Name
Lecanemab-irmb
Substance Name
Lecanemab-irmb
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
LECANEMAB-IRMB 200 mg/mL
Pharmacologic Class
Usage Information
LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with LEQEMBI [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.

Regulatory & Marketing

Labeler Name
Eisai Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761375
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
08-29-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 62856-220-01 identifies a specific commercial package of 1 syringe, plastic in 1 carton / 1.8 ml in 1 syringe, plastic (62856-220-10) of Lecanemab Autoinjector, a human prescription drug labeled by Eisai Inc.. This injection, solution is formulated for subcutaneous use and contains lecanemab-irmb as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eisai Inc. on August 29, 2025. The current certification is valid through December 31, 2027.

How is this Eisai Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 62856022001. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
62856-220-01
11-Digit CMS (5-4-2)
62856-0220-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.